Diffuse large B-cell lymphoma with coexpression of CD3 in a pediatric patient: A case report, review of the literature, and tissue microarray study

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 2, 2009, Pages 124-127

  Wallentine, Jeremy C ^a,d   Perkins, Sherrie L ^a,b   Tripp, Sheryl R ^b   Bruggman, Richard D ^c   Bayerl, Michael G ^c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

CD3 coexpression; Diffuse large B cell lymphoma; Immunohistochemistry; Non Hodgkin lymphoma; T cell antigen coexpression

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; TRANSCRIPTION FACTOR PAX5;

ANAMNESIS; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CD3+ T LYMPHOCYTE; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LUMBAR PUNCTURE; LYMPHOID HYPERPLASIA; MALE; MEDICAL DOCUMENTATION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; TISSUE MICROARRAY; ADOLESCENT; ADULT; AGED; B CELL LYMPHOMA; B LYMPHOCYTE; FEMALE; IMMUNOPHENOTYPING; INFANT; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PSEUDOLYMPHOMA; REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PSEUDOLYMPHOMA; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 60849132503     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818b354a     Document Type: Article

References (20)

1. von der Weid NX. Adult life after surviving lymphoma in childhood. Support Care Cancer. 2008;16:339-345.
2. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13: 193-207.
3. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffinembedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.
4. Inaba T, Shimazaki C, Sumikuma T, et al. T-cell associated antigen-positive B-cell lymphoma. Leuk Lymphoma. 2001;42: 1161-1171.
5. Inaba T, Shimazaki C, Sumikuma T, et al. Expression of T-cell-associated antigens in B-cell non-Hodgkin's lymphoma. Br J Haematol. 2000;109:592-599.
6. Schmidt CJ, Domenico L, Ward P, et al. Aberrant antigen expression detected by multiparameter three color flow cytometry in intermediate and high grade B-cell lymphomas. Leuk Lymphoma. 1999;34:539-544.
7. Newell JO, Cessna MH, Greenwood J, et al. Importance of CD117 in the evaluation of acute leukemias by flow cytometry. Cytometry B Clin Cytom. 2003;52:40-43.
8. Blakolmer K, Vesely M, Kummer JA, et al. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol. 2000;13:766-772.
9. Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110.
10. Petitjean B, Jardin F, Joly B, et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B and T-cell phenotype. Am J Surg Pathol. 2002;26:724-732.
11. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007;20:310-319.
12. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806-815.
13. Fuxa M, Skok JA. Transcriptional regulation in early B cell development. Curr Opin Immunol. 2007;19:129-136.
14. Souabni A, Cobaleda C, Schebesta M, et al. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity. 2002;17:781-793.
15. Delogu A, Schebesta A, Sun Q, et al. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006;24:269-281.
16. Schebesta M, Heavey B, Busslinger M. Transcriptional control of B-cell development. Curr Opin Immunol. 2002;14: 216-223.
17. Hansson M, Jerkeman M, Dictor M. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers. Eur J Haematol. 2007;79:159-165.
18. Poppe B, De Paepe P, Michaux L, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer. 2005;44:218-223.
19. Souabni A, Jochum W, Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood. 2007;109: 281-289.
20. Transy C, Moingeon PE, Marshall B, et al. Most anti-human CD3 monoclonal antibodies are directed to the CD3 epsilon subunit. Eur J Immunol. 1989;19:947-950.